Xeris Biopharma

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) is a growth-oriented biopharmaceutical company improving patient lives by developing and commercializing advanced products across a range of therapies. Xeris markets three FDA-approved products: Gvoke (glucagon) HypoPen, the first FDA-approved autoinjector for severe hypoglycemia; Keveyis (dichlorphenamide), the first FDA-approved treatment for primary periodic paralysis; and Recorlev (levoketoconazole), a cortisol synthesis inhibitor for Cushing's syndrome. Founded in 2005 and incorporated in Delaware, Xeris leverages proprietary formulation technology platforms across endocrinology, neurology, and gastroenterology.